Urinary Tract Infection Therapeutics: By Indication (Complicated UTI, Uncomplicated UTI and Other), By Drug Type (Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitro furans and Other) And Region – Global Analysis of Market Size, Share & Trends for 2019–2020 And Forecasts to 2031
Urinary Tract Infection Therapeutics: By Indication (Complicated UTI, Uncomplicated UTI and Other), By Drug Type (Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitro furans and Other) And Region – Global Analysis of Market Size, Share & Trends for 2019–2020 And Forecasts to 2031
PRODUCT OVERVIEW
UTI (Urinary tract infection) is among the most common health problems. Because women encounter health issues such as menstruation, pregnancy, and some birth control side effects, UTI is much more common among women than in males. A person who has diabetes and then develops urological health problems is inextricably linked. Diabetes exacerbates health problems and increases the chance of UTIs, as well as bladder problems. Diabetes can also cause and result in the worsening of complications such as urologic difficulties and diseases. This is due to the fact that they are known to affect an individual's blood flow, neuron functions, and sensory processes.
MARKET HIGHLIGHTS
Global Urinary Tract Infection Therapeutics market is expected to project a notable CAGR of 3.7% in 2031.
Global Urinary Tract Infection Therapeutics to surpass USD 10.6 billion by 2031 from USD 7.4 billion in 2021 at a CAGR of 3.7% in the coming years, i.e., 2021-31. As the prevalence of diabetes & kidney stones rises, so does the majority of cases of urinary tract infection, which drives up medicine demand and hence propels the worldwide urinary infection therapeutic market.
GLOBAL URINARY TRACT INFECTION THERAPEUTICS: SEGMENTS
Uncomplicated UTI segment to grow with the highest CAGR during 2021-31
Based on indication global Urinary Tract Infection Therapeutics is categorized into Complicated UTI, Uncomplicated UTI and Other. The uncomplicated UTI market accounts the highest market growth. The most frequent type of UTI now impacting the worldwide population is uncomplicated UTIs. Antibiotics are usually prescribed to treat UTIs. Because of the rising number of hospital-acquired infections, particularly catheter-associated UTIs, the uncomplicated UTI category is expected to lead the global urinary tract infection therapies in the coming year.
Quinolones segment to grow with the highest CAGR during 2021-31
Global Urinary Tract Infection Therapeutics is segmented in the basis of Drug type into Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitro furans and Other. The quinolones category retained the greatest share of the market, which also consist of penicillin and combination sector is expected to grow at the fastest rate over the forecast period. As they are available in hospital and retail pharmacies. The fact that quinolones are routinely recommended by physicians is largely responsible for the market's future growth. Fluoroquinolones, ofloxacin, & enoxacins are among the most commonly prescribed antibiotics
MARKET DYNAMICS
Drivers
Increasing in prevalence of UTIs
Rising demand for Antibiotic consumption
Restraint
Complicated legal obligations
GLOBAL URINARY TRACT INFECTION THERAPEUTICS:
Key Players
Global Urinary Tract Infection Therapeutics market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. The North American region includes countries that results in the growth of the global urine tract infection therapeutic market. The North American market is anticipating a significant increase in investment in research & development of treatment goods and diagnostics that will aid in the global expansion of the urinary tract infection (UTI) industry. Because of the expanding prevalence of Urinary infections and renal issues among the populations of this region, the United States has a growing global market share.
IMPACT OF COVID-19 ON URINARY TRACT INFECTION THERAPEUTICS MARKET
The unexpected rise of coronavirus-infected patients hampered access to other primary care treatments, resulting in a large decline in non-COVID-19-related diagnoses such urinary tract infection. In 2020, the rate of UTI diagnostic decreased somewhat, possibly slowing the industry's expansion in recent months. A considerable decline in urinary infection (UTI) diagnosis associated to the COVID-19 pandemic is cause for concern. As a result, fewer people sought primary care services, and fewer diagnoses, such as UTIs.
GLOBAL URINARY TRACT INFECTION THERAPEUTICS REPORT ALSO CONTAINS ANALYSIS ON:
Urinary Tract Infection Therapeutics Segments:
PRODUCT OVERVIEW
UTI (Urinary tract infection) is among the most common health problems. Because women encounter health issues such as menstruation, pregnancy, and some birth control side effects, UTI is much more common among women than in males. A person who has diabetes and then develops urological health problems is inextricably linked. Diabetes exacerbates health problems and increases the chance of UTIs, as well as bladder problems. Diabetes can also cause and result in the worsening of complications such as urologic difficulties and diseases. This is due to the fact that they are known to affect an individual's blood flow, neuron functions, and sensory processes.
MARKET HIGHLIGHTS
Global Urinary Tract Infection Therapeutics market is expected to project a notable CAGR of 3.7% in 2031.
Global Urinary Tract Infection Therapeutics to surpass USD 10.6 billion by 2031 from USD 7.4 billion in 2021 at a CAGR of 3.7% in the coming years, i.e., 2021-31. As the prevalence of diabetes & kidney stones rises, so does the majority of cases of urinary tract infection, which drives up medicine demand and hence propels the worldwide urinary infection therapeutic market.
GLOBAL URINARY TRACT INFECTION THERAPEUTICS: SEGMENTS
Uncomplicated UTI segment to grow with the highest CAGR during 2021-31
Based on indication global Urinary Tract Infection Therapeutics is categorized into Complicated UTI, Uncomplicated UTI and Other. The uncomplicated UTI market accounts the highest market growth. The most frequent type of UTI now impacting the worldwide population is uncomplicated UTIs. Antibiotics are usually prescribed to treat UTIs. Because of the rising number of hospital-acquired infections, particularly catheter-associated UTIs, the uncomplicated UTI category is expected to lead the global urinary tract infection therapies in the coming year.
Quinolones segment to grow with the highest CAGR during 2021-31
Global Urinary Tract Infection Therapeutics is segmented in the basis of Drug type into Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitro furans and Other. The quinolones category retained the greatest share of the market, which also consist of penicillin and combination sector is expected to grow at the fastest rate over the forecast period. As they are available in hospital and retail pharmacies. The fact that quinolones are routinely recommended by physicians is largely responsible for the market's future growth. Fluoroquinolones, ofloxacin, & enoxacins are among the most commonly prescribed antibiotics
MARKET DYNAMICS
Drivers
Increasing in prevalence of UTIs
Rising demand for Antibiotic consumption
Restraint
Complicated legal obligations
GLOBAL URINARY TRACT INFECTION THERAPEUTICS:
Key Players
- Allergan
- Bayer AG
- Pfizer, Inc.
- GlaxoSmithKline plc
- Bristol-Myers Squibb Company
- Janssen Global Services, LLC
- Lupin Ltd.
- Merck & Co., Inc
- Almirall, S.A
- Other Prominent Players
Global Urinary Tract Infection Therapeutics market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. The North American region includes countries that results in the growth of the global urine tract infection therapeutic market. The North American market is anticipating a significant increase in investment in research & development of treatment goods and diagnostics that will aid in the global expansion of the urinary tract infection (UTI) industry. Because of the expanding prevalence of Urinary infections and renal issues among the populations of this region, the United States has a growing global market share.
IMPACT OF COVID-19 ON URINARY TRACT INFECTION THERAPEUTICS MARKET
The unexpected rise of coronavirus-infected patients hampered access to other primary care treatments, resulting in a large decline in non-COVID-19-related diagnoses such urinary tract infection. In 2020, the rate of UTI diagnostic decreased somewhat, possibly slowing the industry's expansion in recent months. A considerable decline in urinary infection (UTI) diagnosis associated to the COVID-19 pandemic is cause for concern. As a result, fewer people sought primary care services, and fewer diagnoses, such as UTIs.
GLOBAL URINARY TRACT INFECTION THERAPEUTICS REPORT ALSO CONTAINS ANALYSIS ON:
Urinary Tract Infection Therapeutics Segments:
- By Indication
- Complicated UTI,
- Uncomplicated UTI
- Other
- By Drug Type
- Quinolones
- Cephalosporin
- Azoles
- Amphotericin B
- Nitro furans
- Other
- Urinary Tract Infection Therapeutics Dynamics
- Urinary Tract Infection Therapeutics Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved in the Market
- Value Chain of the Market
- Market Drivers and Restraints
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 3-month post-sales analyst support.
1.EXECUTIVE SUMMARY
1.1. Regional Market Share
1.2. Business Trends
1.3. Global Urinary Tract Infection Therapeutics Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2 RESEARCH METHODOLOGY
2.1. Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3 MARKET CHARACTERISTICS
3.1. Market Definition
3.2. Global Urinary Tract Infection Therapeutics Market: COVID-19 Impact
3.3. Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4 GLOBAL URINARY TRACT INFECTION THERAPEUTICS MARKET – INDUSTRY INSIGHTS
4.1. Industry Segmentation
4.2. COVID-19 overview on world economy
4.3. Industry ecosystem Channel analysis
4.4. Innovation & Sustainability
5 MACROECONOMIC INDICATORS
6 RECENT DEVELOPMENTS
7 MARKET DYNAMICS
7.1. Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4. Market Restraints
7.5. Market Trends
8 RISK ANALYSIS
9 MARKET ANALYSIS
9.1. Porters Five Forces
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10 GLOBAL URINARY TRACT INFECTION THERAPEUTICS MARKET
10.1. Overview
10.2. Historical Analysis (2016-2020)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11 GLOBAL URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F
11.1. Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Indication
11.3.1.1. Complicated UTI
11.3.1.1.1. By Value (USD Million) 2021-2031F
11.3.1.1.2. Market Share (%) 2021-2031F
11.3.1.1.3. Y-o-Y Growth (%) 2021-2031F
11.3.1.2. Uncomplicated UTI
11.3.1.2.1. By Value (USD Million) 2021-2031F
11.3.1.2.2. Market Share (%) 2021-2031F
11.3.1.2.3. Y-o-Y Growth (%) 2021-2031F
11.3.1.3. Other
11.3.1.3.1. By Value (USD Million) 2021-2031F
11.3.1.3.2. Market Share (%) 2021-2031F
11.3.1.3.3. Y-o-Y Growth (%) 2021-2031F
11.3.2. By Drug Type
11.3.2.1. Quinolones
11.3.2.1.1. By Value (USD Million) 2021-2031F
11.3.2.1.2. Market Share (%) 2021-2031F
11.3.2.1.3. Y-o-Y Growth (%) 2021-2031F
11.3.2.2. Cephalosporin
11.3.2.2.1. By Value (USD Million) 2021-2031F
11.3.2.2.2. Market Share (%) 2021-2031F
11.3.2.2.3. Y-o-Y Growth (%) 2021-2031F
11.3.2.3. Azoles and Amphotericin B
11.3.2.3.1. By Value (USD Million) 2021-2031F
11.3.2.3.2. Market Share (%) 2021-2031F
11.3.2.3.3. Y-o-Y Growth (%) 2021-2031F
11.3.2.4. Nitro furans
11.3.2.4.1. By Value (USD Million) 2021-2031F
11.3.2.4.2. Market Share (%) 2021-2031F
11.3.2.4.3. Y-o-Y Growth (%) 2021-2031F
11.3.2.5. Other
11.3.2.5.1. By Value (USD Million) 2021-2031F
11.3.2.5.2. Market Share (%) 2021-2031F
11.3.2.5.3. Y-o-Y Growth (%) 2021-2031F
12 NORTH AMERICA URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Indication
12.3.2. By Drug Type
12.4. Country
12.4.1. United States
12.4.2. Canada
13 EUROPE URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. Indication
13.3.2. By Drug Type
13.4. Country
13.4.1. Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14 ASIA URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F
14.1. Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Indication
14.3.2. By Drug Type
14.4. Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15 MIDDLE EAST AND AFRICA URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F
15.1. Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Indication
15.3.2. By Drug Type
15.4. Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4. South Africa
15.4.5. Rest of Middle East and Africa
16 LATIN AMERICA URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Indication
16.3.2. By Drug Type
16.4. Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17 COMPETITIVE LANDSCAPE
17.1. Company market share, 2021
17.2. Key player overview
17.3. Key stakeholders
18 COMPANY PROFILES
18.1. Allergan
18.1.1. Company Overview
18.1.2. Financial Overview
18.1.3. Key Product; Analysis
18.1.4. Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2. Bayer AG
18.3. Pfizer, Inc.
18.4. GlaxoSmithKline plc
18.5. Bristol-Myers Squibb Company
18.6. Janssen Global Services, LLC
18.7. Lupin Ltd.
18.8. Merck & Co., Inc
18.9. Almirall, S.A
18.10. Other Prominent Players
19 APPENDIX
20 CONSULTANT RECOMMENDATION
1.1. Regional Market Share
1.2. Business Trends
1.3. Global Urinary Tract Infection Therapeutics Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2 RESEARCH METHODOLOGY
2.1. Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3 MARKET CHARACTERISTICS
3.1. Market Definition
3.2. Global Urinary Tract Infection Therapeutics Market: COVID-19 Impact
3.3. Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4 GLOBAL URINARY TRACT INFECTION THERAPEUTICS MARKET – INDUSTRY INSIGHTS
4.1. Industry Segmentation
4.2. COVID-19 overview on world economy
4.3. Industry ecosystem Channel analysis
4.4. Innovation & Sustainability
5 MACROECONOMIC INDICATORS
6 RECENT DEVELOPMENTS
7 MARKET DYNAMICS
7.1. Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4. Market Restraints
7.5. Market Trends
8 RISK ANALYSIS
9 MARKET ANALYSIS
9.1. Porters Five Forces
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10 GLOBAL URINARY TRACT INFECTION THERAPEUTICS MARKET
10.1. Overview
10.2. Historical Analysis (2016-2020)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11 GLOBAL URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F
11.1. Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Indication
11.3.1.1. Complicated UTI
11.3.1.1.1. By Value (USD Million) 2021-2031F
11.3.1.1.2. Market Share (%) 2021-2031F
11.3.1.1.3. Y-o-Y Growth (%) 2021-2031F
11.3.1.2. Uncomplicated UTI
11.3.1.2.1. By Value (USD Million) 2021-2031F
11.3.1.2.2. Market Share (%) 2021-2031F
11.3.1.2.3. Y-o-Y Growth (%) 2021-2031F
11.3.1.3. Other
11.3.1.3.1. By Value (USD Million) 2021-2031F
11.3.1.3.2. Market Share (%) 2021-2031F
11.3.1.3.3. Y-o-Y Growth (%) 2021-2031F
11.3.2. By Drug Type
11.3.2.1. Quinolones
11.3.2.1.1. By Value (USD Million) 2021-2031F
11.3.2.1.2. Market Share (%) 2021-2031F
11.3.2.1.3. Y-o-Y Growth (%) 2021-2031F
11.3.2.2. Cephalosporin
11.3.2.2.1. By Value (USD Million) 2021-2031F
11.3.2.2.2. Market Share (%) 2021-2031F
11.3.2.2.3. Y-o-Y Growth (%) 2021-2031F
11.3.2.3. Azoles and Amphotericin B
11.3.2.3.1. By Value (USD Million) 2021-2031F
11.3.2.3.2. Market Share (%) 2021-2031F
11.3.2.3.3. Y-o-Y Growth (%) 2021-2031F
11.3.2.4. Nitro furans
11.3.2.4.1. By Value (USD Million) 2021-2031F
11.3.2.4.2. Market Share (%) 2021-2031F
11.3.2.4.3. Y-o-Y Growth (%) 2021-2031F
11.3.2.5. Other
11.3.2.5.1. By Value (USD Million) 2021-2031F
11.3.2.5.2. Market Share (%) 2021-2031F
11.3.2.5.3. Y-o-Y Growth (%) 2021-2031F
12 NORTH AMERICA URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Indication
12.3.2. By Drug Type
12.4. Country
12.4.1. United States
12.4.2. Canada
13 EUROPE URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. Indication
13.3.2. By Drug Type
13.4. Country
13.4.1. Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14 ASIA URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F
14.1. Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Indication
14.3.2. By Drug Type
14.4. Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15 MIDDLE EAST AND AFRICA URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F
15.1. Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Indication
15.3.2. By Drug Type
15.4. Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4. South Africa
15.4.5. Rest of Middle East and Africa
16 LATIN AMERICA URINARY TRACT INFECTION THERAPEUTICS MARKET SIZE & FORECAST 2021A-2031F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Indication
16.3.2. By Drug Type
16.4. Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17 COMPETITIVE LANDSCAPE
17.1. Company market share, 2021
17.2. Key player overview
17.3. Key stakeholders
18 COMPANY PROFILES
18.1. Allergan
18.1.1. Company Overview
18.1.2. Financial Overview
18.1.3. Key Product; Analysis
18.1.4. Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2. Bayer AG
18.3. Pfizer, Inc.
18.4. GlaxoSmithKline plc
18.5. Bristol-Myers Squibb Company
18.6. Janssen Global Services, LLC
18.7. Lupin Ltd.
18.8. Merck & Co., Inc
18.9. Almirall, S.A
18.10. Other Prominent Players
19 APPENDIX
20 CONSULTANT RECOMMENDATION
